Synergy between Clinical Microenvironment Targeted Nanoplatform and Near-Infrared Light Irradiation for Managing Pseudomonas aeruginosa Infections
Source abstract
Abstract
Chronic infections caused by Pseudomonas aeruginosa pose severe threats to human health. Traditional antibiotic therapy has lost its total supremacy in this battle. Here, nanoplatforms activated by the clinical microenvironment are developed to treat P. aeruginosa infection on the basis of dynamic borate ester bonds. In this design, the nanoplatforms expose targeted groups for bacterial capture after activation by an acidic infection microenvironment, resulting in directional transport delivery of the payload to bacteria. Subsequently, the production of hyperpyrexia and reactive oxygen species enhances antibacterial efficacy without systemic toxicity. Such a formulation with a diameter less than 200 nm can eliminate biofilm up to 75%, downregulate the level of cytokines, and finally promote lung repair. Collectively, the biomimetic design with phototherapy killing capability has the potential to be an alternative strategy against chronic infections caused by P. aeruginosa.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Bacterial biofilms and quorum sensing · Inhalation and Respiratory Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Functional Polymer Materials of Ministry of Education, Institute of Polymer Chemistry, College of Chemistry, Nankai University, Tianjin 300071, China
NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300134, China
Funding
National Natural Science Foundation of China
References (53)
Show source-provided references
1. 10.1002/anie.20140927010.1002/anie.201409270 ↗
2. 10.1002/adfm.20180698610.1002/adfm.201806986 ↗
3. 10.1016/j.micpath.2018.07.02010.1016/j.micpath.2018.07.020 ↗
4. 10.1002/phar.233410.1002/phar.2334 ↗
5. 10.1111/j.1469-0691.2005.01196.x10.1111/j.1469-0691.2005.01196.x ↗
6. 10.1002/adfm.20170225510.1002/adfm.201702255 ↗
7. 10.1002/adfm.20120292710.1002/adfm.201202927 ↗
8. 10.1038/mi.2016.10810.1038/mi.2016.108 ↗
9. 10.1111/1462-2920.1216410.1111/1462-2920.12164 ↗
10. 10.1038/s41467-019-08733-w10.1038/s41467-019-08733-w ↗
11. 10.1039/C6NJ03260E10.1039/C6NJ03260E ↗
12. 10.1021/acsami.8b1609210.1021/acsami.8b16092 ↗
13. 10.1039/C8NR07146B10.1039/C8NR07146B ↗
14. 10.1021/acsabm.8b0057710.1021/acsabm.8b00577 ↗
15. 10.1002/adma.20170164410.1002/adma.201701644 ↗
16. 10.3389/fmicb.2018.0075410.3389/fmicb.2018.00754 ↗
17. Trial J. · Inflammation Cell Signaling · 2016 · 3 · e1409
18. 10.1039/C9CC05086H10.1039/C9CC05086H ↗
19. 10.1002/adfm.20190904210.1002/adfm.201909042 ↗
20. 10.1021/acsbiomaterials.7b0072310.1021/acsbiomaterials.7b00723 ↗
21. 10.1038/s41467-019-10778-w10.1038/s41467-019-10778-w ↗
22. 10.1111/jcmm.1277810.1111/jcmm.12778 ↗
23. 10.3389/fmicb.2015.0096310.3389/fmicb.2015.00963 ↗
24. 10.1021/acsami.7b1567810.1021/acsami.7b15678 ↗
25. 10.1016/j.ijmm.2008.08.00310.1016/j.ijmm.2008.08.003 ↗
26. 10.1021/acs.molpharmaceut.6b0105110.1021/acs.molpharmaceut.6b01051 ↗
27. 10.1021/acs.molpharmaceut.6b0114610.1021/acs.molpharmaceut.6b01146 ↗
28. 10.1021/ma034321h10.1021/ma034321h ↗
29. 10.1021/ac049334n10.1021/ac049334n ↗
30. 10.1021/ma034010710.1021/ma0340107 ↗
31. 10.1021/ma060374y10.1021/ma060374y ↗
32. 10.1371/journal.ppat.100028210.1371/journal.ppat.1000282 ↗
33. 10.1002/ange.20170339810.1002/ange.201703398 ↗
34. 10.1128/IAI.01204-0810.1128/IAI.01204-08 ↗
35. 10.1021/acs.jmedchem.6b0143510.1021/acs.jmedchem.6b01435 ↗
36. 10.1021/acsnano.7b0320710.1021/acsnano.7b03207 ↗
37. 10.1021/acsnano.6b0873110.1021/acsnano.6b08731 ↗
38. 10.1021/nn400334y10.1021/nn400334y ↗
39. 10.1021/acs.chemmater.8b0114910.1021/acs.chemmater.8b01149 ↗
40. 10.1021/ja400970n10.1021/ja400970n ↗
41. 10.1021/acs.jmedchem.5b0169810.1021/acs.jmedchem.5b01698 ↗
42. 10.1021/acsami.9b0578710.1021/acsami.9b05787 ↗
43. 10.1016/j.isci.2021.10244310.1016/j.isci.2021.102443 ↗
44. 10.1039/C5MD00373C10.1039/C5MD00373C ↗
45. 10.1002/adma.20180602410.1002/adma.201806024 ↗
46. 10.1016/j.dci.2018.08.01210.1016/j.dci.2018.08.012 ↗
47. 10.1039/C9NR05865F10.1039/C9NR05865F ↗
48. 10.1128/IAI.00883-0910.1128/IAI.00883-09 ↗
49. 10.1101/gad.122870410.1101/gad.1228704 ↗
50. 10.1016/j.cell.2010.01.02210.1016/j.cell.2010.01.022 ↗
51. 10.1016/S0008-6363(01)00354-610.1016/S0008-6363(01)00354-6 ↗
52. 10.1016/S0140-6736(03)14075-510.1016/S0140-6736(03)14075-5 ↗
53. 10.1021/acs.molpharmaceut.5b0073410.1021/acs.molpharmaceut.5b00734 ↗